Charles River Laboratories (CRL) recently announced layoffs at its Wilmington HQ, as it faces lower guidance and weak earnings. The company's stock has underperformed against competitors, which led Wellington Management Group LLP to reduce their stake in CRL. However, the laboratory provided an update on their strategic review, hinting at a potential shift in their investment narrative.
CRL plans to sell off its underperforming business segments, following a review. They also announced a $1B buyback plan and share price recovery after recent volatility. Charles River has also initiated new drug discovery collaborations, thus boosting its prospects for innovation.
The labs are also being investigated by the former Louisiana Attorney general, raising concerns among stockholders. Despite this, the company remains confident, especially after redefining their edge in biotech collaboration through novel ADC partnerships and science partnerships geared towards non-animal testing.
Charles River Laboratories International CRL News Analytics from Mon, 24 Mar 2025 07:00:00 GMT to Sat, 15 Nov 2025 02:39:40 GMT - Rating -5 - Innovation 3 - Information 7 - Rumor -8
